{"id":"https://openalex.org/W4388565841","doi":"https://doi.org/10.1080/13543784.2023.2283020","title":"Retatrutide showing promise in obesity (and type 2 diabetes)","display_name":"Retatrutide showing promise in obesity (and type 2 diabetes)","alternate_titles":[],"publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4388565841","doi":"https://doi.org/10.1080/13543784.2023.2283020","pmid":"https://pubmed.ncbi.nlm.nih.gov/37947489"},"language":"en","primary_location":{"id":"doi:10.1080/13543784.2023.2283020","doi":"https://doi.org/10.1080/13543784.2023.2283020","is_oa":false,"landing_page_url":"https://doi.org/10.1080/13543784.2023.2283020","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4388565841"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071085963","display_name":"Sheila Anne Doggrell","orcid":"https://orcid.org/0000-0002-0942-0795","observed_orcids":["https://orcid.org/0000-0002-0942-0795","https://orcid.org/0000-0003-4665-4483"]},"institutions":[{"id":"https://openalex.org/I11701301","display_name":"Griffith University","ror":"https://ror.org/02sc3r913","country_code":"AU","type":"education","lineage":["https://openalex.org/I11701301"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Sheila A Doggrell","raw_affiliation_strings":["School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Queensland, Australia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"School of Pharmacy and Medical Sciences, Gold Coast Campus, Griffith University, Queensland, Australia","institution_ids":["https://openalex.org/I11701301"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5071085963"],"corresponding_institution_ids":["https://openalex.org/I11701301"],"apc_list":null,"apc_paid":null,"fwci":2.0322,"has_fulltext":false,"cited_by_count":17,"citation_normalized_percentile":{"value":0.85431607,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":97,"max":98},"biblio":{"volume":"32","issue":"11","first_page":"997","last_page":"1001"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.9696999788284302,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.02850000001490116,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10489","display_name":"Regulation of Appetite and Obesity","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2807","display_name":"Endocrine and Autonomic Systems"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/retatrutide","display_name":"retatrutide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.8450000286102295},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9980000257492065},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9179999828338623},{"id":"https://openalex.org/keywords/gip-receptor","display_name":"GIP receptor","score":0.7749999761581421},{"id":"https://openalex.org/keywords/glucagon-receptor","display_name":"glucagon receptor","score":0.9860000014305115},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.9610000252723694},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6899999976158142},{"id":"https://openalex.org/keywords/heart-rate","display_name":"heart rate","score":0.6909999847412109},{"id":"https://openalex.org/keywords/semaglutide","display_name":"semaglutide","score":0.9789999723434448},{"id":"https://openalex.org/keywords/tirzepatide","display_name":"tirzepatide","score":0.9160000085830688},{"id":"https://openalex.org/keywords/anti-obesity-drugs","display_name":"anti-obesity drugs","score":0.5740000009536743}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6772089004516602},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.6742949485778809},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.6629663109779358},{"id":"https://openalex.org/C511355011","wikidata":"https://www.wikidata.org/wiki/Q12174","display_name":"Obesity","level":2,"score":0.6576588749885559},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.6464800238609314},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6345001459121704},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6269627809524536},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.5497369170188904},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.4839070737361908}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D009765","descriptor_name":"Obesity","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D012307","descriptor_name":"Risk Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015431","descriptor_name":"Weight Loss","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1080/13543784.2023.2283020","doi":"https://doi.org/10.1080/13543784.2023.2283020","is_oa":false,"landing_page_url":"https://doi.org/10.1080/13543784.2023.2283020","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:37947489","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/37947489","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W2425644022","https://openalex.org/W2778441902","https://openalex.org/W2906096545","https://openalex.org/W3095909321","https://openalex.org/W3127371223","https://openalex.org/W3177393241","https://openalex.org/W4206445899","https://openalex.org/W4281934192","https://openalex.org/W4292242922","https://openalex.org/W4307648695","https://openalex.org/W4366742421","https://openalex.org/W4381598155","https://openalex.org/W4381953540","https://openalex.org/W4382049661","https://openalex.org/W4382051781"],"related_works":["https://openalex.org/W4366742421","https://openalex.org/W4409539754","https://openalex.org/W7133696591","https://openalex.org/W7214729877","https://openalex.org/W4400737015","https://openalex.org/W4407175317","https://openalex.org/W4388023373","https://openalex.org/W7204496788","https://openalex.org/W4403214002","https://openalex.org/W7220968603"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Obesity":[1],"is":[2,30,148,184],"a":[3,118,152,185],"major":[4,186],"risk":[5],"factor":[6],"for":[7,33,103,108],"cardiovascular":[8],"disease,":[9],"diabetes,":[10],"osteoarthritis,":[11],"and":[12,26,29,38,137,171],"some":[13,139],"cancers.":[14],"Retatrutide":[15],"stimulates":[16],"Glucagon-like":[17],"peptide":[18],"1":[19,84],"(GLP-1),":[20],"Glucose-dependent":[21],"insulinotropic":[22],"polypeptide":[23],"(GIP)":[24],"receptors,":[25,28],"glucagon":[27],"being":[31,117,149],"developed":[32,150,157],"the":[34,53,78,141,155,189],"treatment":[35,54],"of":[36,49,55,80,140,143,191],"obesity":[37,109],"type":[39],"2":[40,46,107],"diabetes.":[41],"AREAS":[42],"COVERED:":[43],"A":[44],"phase":[45,106],"clinical":[47],"trial":[48],"retatrutide":[50,81,104,147,170],"(LY3437943)":[51],"in":[52,64,105,179,188],"obesity.":[56],"The":[57,89,101],"primary":[58],"end":[59],"point":[60],"was":[61,124],"percentage":[62],"change":[63],"weight":[65,144,158],"from":[66,73,83],"baseline":[67],"to":[68,75,86,128,154],"24":[69],"weeks,":[70],"which":[71,133],"ranged":[72],"-7.2%":[74],"-~18%":[76],"as":[77,151],"dose":[79],"increased":[82,125],"mg":[85],"12":[87],"mg.":[88],"most":[90],"frequent":[91],"adverse":[92],"events":[93],"were":[94],"gastrointestinal":[95],"(nausea,":[96],"diarrhea,":[97],"vomiting).":[98],"EXPERT":[99],"OPINION:":[100],"results":[102],"(and":[110],"diabetes)":[111],"are":[112,167,176],"mostly":[113],"encouraging.":[114],"Consistent":[115],"with":[116],"GLP-1":[119],"receptor":[120],"agonist,":[121],"heart":[122],"rate":[123],"by":[126,131],"up":[127],"6.7":[129],"beats/min":[130],"retatrutide,":[132],"may":[134],"be":[135],"detrimental":[136],"offset":[138],"benefits":[142],"loss.":[145],"Presumably,":[146],"challenger":[153],"recently":[156],"loss":[159],"medicines;":[160],"semaglutide":[161],"and/or":[162],"tirzepatide.":[163],"Thus,":[164],"comparator":[165],"studies":[166],"needed":[168],"between":[169],"these":[172],"drugs,":[173],"but":[174],"none":[175],"ongoing":[177],"and,":[178],"my":[180],"opinion,":[181],"this":[182],"lack":[183],"omission":[187],"development":[190],"retatrutide.":[192]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4388565841","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":7}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-11-11T00:00:00"}
